Literature DB >> 8624578

Prognostic relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer.

H Ito1, Y Yonemura, H Fujita, K Tsuchihara, T Kawamura, N Nojima, T Fujimura, H Nose, Y Endo, T Sasaki.   

Abstract

Expression of urokinase-type plasminogen activator (uPA), plasminogen activator inhibitor-1 (PAI-1) and plasminogen activator inhibitor-2 (PAI-2) was evaluated in 125 surgically resected gastric cancers by immunohistochemical analysis. Tissue was stained immunohistochemically with a monoclonal antibody against human uPA and monoclonal antibodies against human PAI-1 and PAI-2. In addition, DNA ploidy patterns were determined by cytofluorometer after staining with propidium iodide. We found that 82 (66%) of the 125 gastric cancers expressed uPA as diffuse cytoplasmic staining, as intensely outlined luminal borders. PAI-1 expression was observed in 62 (50%) of 125 gastric cancer as a fine, diffuse and granular pattern in the cytoplasm. PAI-2 expression was observed in 65 (52%) of the 125 gastric cancers as a diffuse cytoplasmic staining. uPA-positive tumours showed a higher incidence of infiltration, lymph node metastasis and peritoneal dissemination that uPA-negative ones. Patients with uPA-positive tumours proved to have a significantly poorer prognosis than those with negative ones. PAI-1-negative tumours showed a higher incidence of liver metastasis and carried a poorer prognosis than PAI-1-positive ones. There was no significant correlation between uPA or PAI-1 expression and DNA ploidy patterns. Conversely, there was no significant relationship between PAI-2 expression and clinicopathological parameters and prognosis. According to the expression of uPA and PAI-1 status, groups of 19 uPA(-)/PAI-1(-), 44 uPA(+)/PAI-1(-), 23 uPA(-)/PAI-1(+) and 39 uPA(+)/PAI-1(+) were subdivided. Tumours with uPA(+)/PAI-1(-) had a significantly higher incidence of liver metastasis, lymph node metastasis and serosal invasion than the other groups of tumours. Patients with uPA(+)/PAI-1(-) tumours had a significantly poorer prognosis than those with uPA(-)/PAI-1(+) tumours. These results indicate that uPA expression is a useful biological prognostic indicator, and that uPA expression is a useful biological prognostic indicator, and that uPA and PAI-1 may play an important part in the tumour progression and metastasis in gastric cancer.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8624578     DOI: 10.1007/bf00199509

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  63 in total

1.  Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor.

Authors:  D Olson; J Pöllänen; G Høyer-Hansen; E Rønne; K Sakaguchi; T C Wun; E Appella; K Danø; F Blasi
Journal:  J Biol Chem       Date:  1992-05-05       Impact factor: 5.157

2.  Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer.

Authors:  F Jänicke; M Schmitt; H Graeff
Journal:  Semin Thromb Hemost       Date:  1991-07       Impact factor: 4.180

Review 3.  Growth factors in the regulation of pericellular proteolysis: a review.

Authors:  M Laiho; J Keski-Oja
Journal:  Cancer Res       Date:  1989-05-15       Impact factor: 12.701

4.  Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer.

Authors:  M J Duffy; D Reilly; C O'Sullivan; N O'Higgins; J J Fennelly; P Andreasen
Journal:  Cancer Res       Date:  1990-11-01       Impact factor: 12.701

5.  The concentration of tissue plasminogen activator and urokinase in plasma and tissues of patients with ovarian and uterine tumors.

Authors:  K Saito; M Nagashima; M Iwata; H Hamada; K Sumiyoshi; Y Takada; A Takada
Journal:  Thromb Res       Date:  1990-05-15       Impact factor: 3.944

Review 6.  Plasminogen activator inhibitors--a review.

Authors:  E K Kruithof
Journal:  Enzyme       Date:  1988

7.  Plasminogen activator profiles in neoplastic tissues of the human colon.

Authors:  P A de Bruin; G Griffioen; H W Verspaget; J H Verheijen; G Dooijewaard; H F van den Ingh; C B Lamers
Journal:  Cancer Res       Date:  1988-08-15       Impact factor: 12.701

8.  Antibodies to plasminogen activator inhibit human tumor metastasis.

Authors:  L Ossowski; E Reich
Journal:  Cell       Date:  1983-12       Impact factor: 41.582

Review 9.  Flow cytofluorometry in tumour cell receptor analysis. Survey of the literature and recent developments concerning the urokinase-type plasminogen activator (uPA).

Authors:  N Chucholowski; M Schmitt; L Goretzki; E Schüren; N Moniwa; U Weidle; M Kramer; B Wagner; F Jänicke; H Graeff
Journal:  Biochem Soc Trans       Date:  1992-02       Impact factor: 5.407

10.  Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1.

Authors:  M V Cubellis; T C Wun; F Blasi
Journal:  EMBO J       Date:  1990-04       Impact factor: 11.598

View more
  13 in total

1.  Immunohistochemical expression of the sialyl Lewis x antigen on gastric cancer cells correlates with the presence of liver metastasis.

Authors:  M Tatsumi; A Watanabe; H Sawada; Y Yamada; Y Shino; H Nakano
Journal:  Clin Exp Metastasis       Date:  1998-11       Impact factor: 5.150

2.  Membrane-type 1 matrix metalloproteinase enhances lymph node metastasis of gastric cancer.

Authors:  Y Yonemura; Y Endo; T Takino; K Sakamoto; E Bandou; K Kinoshita; S Fushida; K Miwa; K Sugiyama; T Sasaki
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

3.  Gastrin stimulates expression of plasminogen activator inhibitor-1 in gastric epithelial cells.

Authors:  Kristin G Nørsett; Islay Steele; Cedric Duval; Stephen J Sammut; Senthil V M Murugesan; Susan Kenny; Lucille Rainbow; Rod Dimaline; Graham J Dockray; D Mark Pritchard; Andrea Varro
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-12-30       Impact factor: 4.052

4.  Urokinase type plasminogen activator receptor expression in colorectal neoplasms.

Authors:  S Suzuki; Y Hayashi; Y Wang; T Nakamura; Y Morita; K Kawasaki; K Ohta; N Aoyama; S R Kim; H Itoh; Y Kuroda; W F Doe
Journal:  Gut       Date:  1998-12       Impact factor: 23.059

5.  Regeneration of small intestinal mucosa after acute ischemia-reperfusion injury.

Authors:  Hiroshi Itoh; Masao Yagi; Ken Hasebe; Sachio Fushida; Takashi Tani; Tetsuo Hashimoto; Kouichi Shimizu; Koichi Miwa
Journal:  Dig Dis Sci       Date:  2002-12       Impact factor: 3.199

6.  Decreased expression of SERPINB1 correlates with tumor invasion and poor prognosis in hepatocellular carcinoma.

Authors:  Xiaopeng Cui; Yanhua Liu; Chunhua Wan; Cuihua Lu; Jing Cai; Song He; Tingting Ni; Junya Zhu; Lixian Wei; Yixin Zhang; Haixin Qian
Journal:  J Mol Histol       Date:  2013-10-09       Impact factor: 2.611

7.  High tPA-expression in primary melanoma of the limb correlates with good prognosis.

Authors:  C M Ferrier; S Suciu; W L van Geloof; H Straatman; A M Eggermont; H S Koops; B B Kroon; F J Lejeune; U R Kleeberg; G N van Muijen; D J Ruiter
Journal:  Br J Cancer       Date:  2000-11       Impact factor: 7.640

8.  Increased expression of the urokinase plasminogen activator system by Helicobacter pylori in gastric epithelial cells.

Authors:  Susan Kenny; Cedric Duval; Stephen J Sammut; Islay Steele; D Mark Pritchard; John C Atherton; Richard H Argent; Rod Dimaline; Graham J Dockray; Andrea Varro
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-07-03       Impact factor: 4.052

9.  Adenoviral gene transfer of angiostatic ATF-BPTI inhibits tumour growth.

Authors:  Pierre Lefesvre; Joline Attema; Dirk van Bekkum
Journal:  BMC Cancer       Date:  2002-07-29       Impact factor: 4.430

10.  Clinical significance of the uPA system in gastric cancer with peritoneal metastasis.

Authors:  Youcheng Ding; Hui Zhang; Mingan Zhong; Zhuqing Zhou; Zhixiang Zhuang; Hua Yin; Xujing Wang; Zhenggang Zhu
Journal:  Eur J Med Res       Date:  2013-08-28       Impact factor: 2.175

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.